JPWO2020005873A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020005873A5 JPWO2020005873A5 JP2020572895A JP2020572895A JPWO2020005873A5 JP WO2020005873 A5 JPWO2020005873 A5 JP WO2020005873A5 JP 2020572895 A JP2020572895 A JP 2020572895A JP 2020572895 A JP2020572895 A JP 2020572895A JP WO2020005873 A5 JPWO2020005873 A5 JP WO2020005873A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridazine
- triazolo
- phenol
- pyrazole
- tetramethylpiperidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 1,2,5,6-tetrahydropyridinyl Chemical group 0.000 claims 278
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 113
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 38
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 38
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 21
- ZXRCAYWYTOIRQS-UHFFFAOYSA-N hydron;phenol;chloride Chemical compound Cl.OC1=CC=CC=C1 ZXRCAYWYTOIRQS-UHFFFAOYSA-N 0.000 claims 21
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 20
- 125000003545 alkoxy group Chemical group 0.000 claims 16
- 125000000623 heterocyclic group Chemical group 0.000 claims 13
- 125000001424 substituent group Chemical group 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 7
- JELQZSVKOONUKD-UHFFFAOYSA-N phenol dihydrochloride Chemical compound Cl.Cl.OC1=CC=CC=C1.OC1=CC=CC=C1 JELQZSVKOONUKD-UHFFFAOYSA-N 0.000 claims 7
- 125000002619 bicyclic group Chemical group 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 125000002950 monocyclic group Chemical group 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 5
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 4
- 125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 3
- 125000000033 alkoxyamino group Chemical group 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical group [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 3
- WFJZBOIOPMOUCB-UHFFFAOYSA-N pyridazine;hydrochloride Chemical compound Cl.C1=CC=NN=C1 WFJZBOIOPMOUCB-UHFFFAOYSA-N 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-tetramethylpiperidine Chemical compound CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 claims 2
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- PUBSMDUBHLYMIX-UHFFFAOYSA-N phenol;dihydrochloride Chemical compound Cl.Cl.OC1=CC=CC=C1 PUBSMDUBHLYMIX-UHFFFAOYSA-N 0.000 claims 2
- DNRXKUPYJHTZJE-UHFFFAOYSA-N phenol;hydrobromide Chemical compound Br.OC1=CC=CC=C1 DNRXKUPYJHTZJE-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- 125000005960 1,4-diazepanyl group Chemical group 0.000 claims 1
- YOUQXTMNMLEWCM-UHFFFAOYSA-N 2-(1-piperidin-4-ylpyrazolo[3,4-c]pyridazin-5-yl)-5-(1H-pyrazol-4-yl)phenol Chemical compound OC1=C(C=CC(=C1)C1=CNN=C1)C1=NN=C2N(N=CC2=C1)C1CCNCC1 YOUQXTMNMLEWCM-UHFFFAOYSA-N 0.000 claims 1
- FVXQGVZLCVMFLE-UHFFFAOYSA-N 2-(1-piperidin-4-ylpyrazolo[3,4-c]pyridazin-5-yl)-5-(1H-pyrazol-4-yl)phenol hydrochloride Chemical compound Cl.Oc1cc(ccc1-c1cc2cnn(C3CCNCC3)c2nn1)-c1cn[nH]c1 FVXQGVZLCVMFLE-UHFFFAOYSA-N 0.000 claims 1
- OLYLBVGBSDAEHV-UHFFFAOYSA-N 2-(1H-pyrazol-4-yl)phenol hydrochloride Chemical compound Cl.Oc1ccccc1-c1cn[nH]c1 OLYLBVGBSDAEHV-UHFFFAOYSA-N 0.000 claims 1
- GDUVBKSVYWFWGV-UHFFFAOYSA-N 2-(1h-pyrazol-4-yl)phenol Chemical compound OC1=CC=CC=C1C1=CNN=C1 GDUVBKSVYWFWGV-UHFFFAOYSA-N 0.000 claims 1
- NJYKXOJRBBASGJ-UHFFFAOYSA-N 2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)triazolo[4,5-c]pyridazin-6-yl]-5-(1,2,4-thiadiazol-5-yl)phenol Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=NC=NS1)O)(C)C)C NJYKXOJRBBASGJ-UHFFFAOYSA-N 0.000 claims 1
- QFFQDEGMTBBEMV-UHFFFAOYSA-N 2-methyl-6-[3-(2,2,6,6-tetramethylpiperidin-4-yl)triazolo[4,5-c]pyridazin-6-yl]-1H-benzimidazol-5-ol Chemical compound C1(NC(CC(N2C3=NN=C(C4=C(O)C=C5NC(=NC5=C4)C)C=C3N=N2)C1)(C)C)(C)C QFFQDEGMTBBEMV-UHFFFAOYSA-N 0.000 claims 1
- VTBHBWBXALXSJK-UHFFFAOYSA-N 3-methyl-6-[3-(2,2,6,6-tetramethylpiperidin-4-yl)triazolo[4,5-c]pyridazin-6-yl]benzimidazol-5-ol Chemical compound N1C(CC(CC1(C)C)N1C2=C(N=N1)C=C(C1=C(O)C=C3N(C=NC3=C1)C)N=N2)(C)C VTBHBWBXALXSJK-UHFFFAOYSA-N 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- YFWCCAXUEVEWBF-UHFFFAOYSA-N 5-(1H-pyrazol-4-yl)-2-[1-(2,2,6,6-tetramethylpiperidin-4-yl)pyrazolo[3,4-c]pyridazin-5-yl]phenol Chemical compound CC1(NC(CC(C1)N1C2=C(C=N1)C=C(C1=CC=C(C=3C=NNC=3)C=C1O)N=N2)(C)C)C YFWCCAXUEVEWBF-UHFFFAOYSA-N 0.000 claims 1
- ZEZSKTLJQHOQSU-UHFFFAOYSA-N 5-(1H-pyrazol-4-yl)-2-[7-(2,2,6,6-tetramethyl-1,3-dihydropyridin-4-yl)thieno[3,2-c]pyridazin-3-yl]phenol Chemical compound N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)C(=CS2)C=1CC(NC(C=1)(C)C)(C)C ZEZSKTLJQHOQSU-UHFFFAOYSA-N 0.000 claims 1
- GIYSUKBTCIPXND-UHFFFAOYSA-N 5-(4-methylpyrazol-1-yl)-2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)triazolo[4,5-c]pyridazin-6-yl]phenol Chemical compound C1(C)(CC(N2C3=C(N=N2)C=C(C2=C(C=C(N4C=C(C=N4)C)C=C2)O)N=N3)CC(C)(C)N1)C GIYSUKBTCIPXND-UHFFFAOYSA-N 0.000 claims 1
- WLVVXZGHMCKLHT-UHFFFAOYSA-N Br.FC1=CC(=C(C=C1C1=CC=C(C=C1)O)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound Br.FC1=CC(=C(C=C1C1=CC=C(C=C1)O)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C WLVVXZGHMCKLHT-UHFFFAOYSA-N 0.000 claims 1
- PXVVRAVHOUCNOQ-UHFFFAOYSA-N BrC1=NNC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound BrC1=NNC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C PXVVRAVHOUCNOQ-UHFFFAOYSA-N 0.000 claims 1
- RMBKEKVHYKCBQU-UHFFFAOYSA-N C(=O)OC1=C(C=CC(=C1)C1=NC=C(C=C1)OC(F)F)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound C(=O)OC1=C(C=CC(=C1)C1=NC=C(C=C1)OC(F)F)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C RMBKEKVHYKCBQU-UHFFFAOYSA-N 0.000 claims 1
- IETUBBFAMCEKDY-UHFFFAOYSA-N C(C)N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound C(C)N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C IETUBBFAMCEKDY-UHFFFAOYSA-N 0.000 claims 1
- XXNQVQXOGYTQAO-UHFFFAOYSA-N C(CC)N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound C(CC)N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C XXNQVQXOGYTQAO-UHFFFAOYSA-N 0.000 claims 1
- WGGHKOLLPVNZPN-VPYROQPTSA-N C(N1N=CC(=C1)C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C)([2H])([2H])[2H] Chemical compound C(N1N=CC(=C1)C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C)([2H])([2H])[2H] WGGHKOLLPVNZPN-VPYROQPTSA-N 0.000 claims 1
- AASTXZYIDCCVHJ-UHFFFAOYSA-N C1(C)(CC(N2C3=C(C=C2)N=C(C2=CC(F)=C(C4=CNN=C4)C=C2F)C=N3)CC(C)(C)N1)C Chemical compound C1(C)(CC(N2C3=C(C=C2)N=C(C2=CC(F)=C(C4=CNN=C4)C=C2F)C=N3)CC(C)(C)N1)C AASTXZYIDCCVHJ-UHFFFAOYSA-N 0.000 claims 1
- ZMKXJPXWSNQLIU-UHFFFAOYSA-N C1(CC1)N1C(C=C(C=C1)C1=CC(=C(C=C1)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)O)=O Chemical compound C1(CC1)N1C(C=C(C=C1)C1=CC(=C(C=C1)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)O)=O ZMKXJPXWSNQLIU-UHFFFAOYSA-N 0.000 claims 1
- MDLNGIZCASBHMN-UHFFFAOYSA-N C1(NC(CC(C1)N1C2=NN=C(C=C2N=N1)C1=CC=C(C=2C=CNC=2)C=C1O)(C)C)(C)C Chemical compound C1(NC(CC(C1)N1C2=NN=C(C=C2N=N1)C1=CC=C(C=2C=CNC=2)C=C1O)(C)C)(C)C MDLNGIZCASBHMN-UHFFFAOYSA-N 0.000 claims 1
- HGNVKFMIZLRXNG-UHFFFAOYSA-N C1(NC(CC(C2=CSC3=CC(C4=CC=C(C=5C=NNC=5)C=C4O)=NN=C23)C1)(C)C)(C)C Chemical compound C1(NC(CC(C2=CSC3=CC(C4=CC=C(C=5C=NNC=5)C=C4O)=NN=C23)C1)(C)C)(C)C HGNVKFMIZLRXNG-UHFFFAOYSA-N 0.000 claims 1
- DMSDXTCCTHPVTI-UHFFFAOYSA-N C1CN(CCN1)C1=CNC2=C1N=NC(=C2)C1=CC=C(C=2C=NNC=2)C=C1O Chemical compound C1CN(CCN1)C1=CNC2=C1N=NC(=C2)C1=CC=C(C=2C=NNC=2)C=C1O DMSDXTCCTHPVTI-UHFFFAOYSA-N 0.000 claims 1
- CXMDEHRGUNSXHR-UHFFFAOYSA-N C=1N=CN2C=1C=C(C=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound C=1N=CN2C=1C=C(C=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C CXMDEHRGUNSXHR-UHFFFAOYSA-N 0.000 claims 1
- IEZREAUMRJSMTC-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3C=N2)C4=C(C=C(C=C4)C5=CC=NC=C5)O)C.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3C=N2)C4=C(C=C(C=C4)C5=CC=NC=C5)O)C.Cl IEZREAUMRJSMTC-UHFFFAOYSA-N 0.000 claims 1
- CJSNRGRIMPZUIK-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3C=N2)C4=C(C=C(C=C4)C5=CN=CC=C5)O)C.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3C=N2)C4=C(C=C(C=C4)C5=CN=CC=C5)O)C.Cl CJSNRGRIMPZUIK-UHFFFAOYSA-N 0.000 claims 1
- AWMVRQRPJPJTOJ-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3C=N2)C4=C(C=C(C=C4)C5=CN=CN=C5)O)C.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3C=N2)C4=C(C=C(C=C4)C5=CN=CN=C5)O)C.Cl AWMVRQRPJPJTOJ-UHFFFAOYSA-N 0.000 claims 1
- CYRDUAAZDRATQT-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=CN6C=CN=C6N=C5)O)C.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=CN6C=CN=C6N=C5)O)C.Cl CYRDUAAZDRATQT-UHFFFAOYSA-N 0.000 claims 1
- HRJAULMCRJPELB-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=CN=NC=C5)O)C.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=CN=NC=C5)O)C.Cl HRJAULMCRJPELB-UHFFFAOYSA-N 0.000 claims 1
- ARPRJAMVDNNOMT-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=NC(=NC=N5)OC)O)C.Cl.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=NC(=NC=N5)OC)O)C.Cl.Cl ARPRJAMVDNNOMT-UHFFFAOYSA-N 0.000 claims 1
- QXZZNERSSNMHDQ-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=NN6C=CN=C6C=C5)O)C.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=NN6C=CN=C6C=C5)O)C.Cl QXZZNERSSNMHDQ-UHFFFAOYSA-N 0.000 claims 1
- KYWXKZFVBMQRQY-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=NN6C=NN=C6C=C5)O)C.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=NN6C=NN=C6C=C5)O)C.Cl KYWXKZFVBMQRQY-UHFFFAOYSA-N 0.000 claims 1
- CSBJUXPHLKVWSL-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC(=NC=C1)C(F)(F)F)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC(=NC=C1)C(F)(F)F)O)(C)C)C CSBJUXPHLKVWSL-UHFFFAOYSA-N 0.000 claims 1
- LLUUWAIXIGURPB-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC=2N(C=C1)N=CN=2)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC=2N(C=C1)N=CN=2)O)(C)C)C LLUUWAIXIGURPB-UHFFFAOYSA-N 0.000 claims 1
- QRPNFWFAESPZOV-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC=2N(C=C1)N=NC=2)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC=2N(C=C1)N=NC=2)O)(C)C)C QRPNFWFAESPZOV-UHFFFAOYSA-N 0.000 claims 1
- SJJFQXDPRPTDDW-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC=C(C=C1)O)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC=C(C=C1)O)O)(C)C)C SJJFQXDPRPTDDW-UHFFFAOYSA-N 0.000 claims 1
- OVGMNSUGWLZSDU-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CN=CS1)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CN=CS1)O)(C)C)C OVGMNSUGWLZSDU-UHFFFAOYSA-N 0.000 claims 1
- XTEXURNNNAMPIJ-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CSC=C1)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CSC=C1)O)(C)C)C XTEXURNNNAMPIJ-UHFFFAOYSA-N 0.000 claims 1
- YBSZMQWTRMGMQI-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=CC=2N(N=1)C=NN=2)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=CC=2N(N=1)C=NN=2)O)(C)C)C YBSZMQWTRMGMQI-UHFFFAOYSA-N 0.000 claims 1
- DXNAKRLUCGVJEU-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1SC=CN=1)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1SC=CN=1)O)(C)C)C DXNAKRLUCGVJEU-UHFFFAOYSA-N 0.000 claims 1
- BSCBHDGQVZTZLE-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1SC=NN=1)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1SC=NN=1)O)(C)C)C BSCBHDGQVZTZLE-UHFFFAOYSA-N 0.000 claims 1
- CDCSEJKBOILEBA-UHFFFAOYSA-N CC1=CC=NN1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CC1=CC=NN1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C CDCSEJKBOILEBA-UHFFFAOYSA-N 0.000 claims 1
- DOHWIWKJZVGRLO-UHFFFAOYSA-N CC1=CN=C(S1)C2=CC(=C(C=C2)C3=NN=C4C(=C3)N=NN4C5CC(NC(C5)(C)C)(C)C)O.Cl Chemical compound CC1=CN=C(S1)C2=CC(=C(C=C2)C3=NN=C4C(=C3)N=NN4C5CC(NC(C5)(C)C)(C)C)O.Cl DOHWIWKJZVGRLO-UHFFFAOYSA-N 0.000 claims 1
- XJEYOUGWYYHRSH-UHFFFAOYSA-N CC1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CC1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C XJEYOUGWYYHRSH-UHFFFAOYSA-N 0.000 claims 1
- PYQQNCSCXQFGMO-UHFFFAOYSA-N CC1=NN(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CC1=NN(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C PYQQNCSCXQFGMO-UHFFFAOYSA-N 0.000 claims 1
- YLJHBGQTZFIKII-UHFFFAOYSA-N CC1=NNC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CC1=NNC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C YLJHBGQTZFIKII-UHFFFAOYSA-N 0.000 claims 1
- COKAZEDTDINQIP-UHFFFAOYSA-N CC=1OC(=CN=1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CC=1OC(=CN=1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C COKAZEDTDINQIP-UHFFFAOYSA-N 0.000 claims 1
- XZMKNTZTVAGYFH-UHFFFAOYSA-N CN(C1=CC=C(C=N1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C Chemical compound CN(C1=CC=C(C=N1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C XZMKNTZTVAGYFH-UHFFFAOYSA-N 0.000 claims 1
- NXEPJRQTRBYXAO-UHFFFAOYSA-N CN(C1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C Chemical compound CN(C1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C NXEPJRQTRBYXAO-UHFFFAOYSA-N 0.000 claims 1
- QTPNFWZMBNTULA-UHFFFAOYSA-N CN1N=C(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CN1N=C(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C QTPNFWZMBNTULA-UHFFFAOYSA-N 0.000 claims 1
- AQEDLCXPALRUPH-UHFFFAOYSA-N CN1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CN1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C AQEDLCXPALRUPH-UHFFFAOYSA-N 0.000 claims 1
- JNKSCAAIDAPBDP-UHFFFAOYSA-N CN1N=CC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CN1N=CC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C JNKSCAAIDAPBDP-UHFFFAOYSA-N 0.000 claims 1
- HAHUVWOHNUHKIM-UHFFFAOYSA-N CNC1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CNC1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C HAHUVWOHNUHKIM-UHFFFAOYSA-N 0.000 claims 1
- ZNSFSXYSTJPUPK-UHFFFAOYSA-N COC1=NC(=NC=N1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound COC1=NC(=NC=N1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C ZNSFSXYSTJPUPK-UHFFFAOYSA-N 0.000 claims 1
- MKKLUEGHXQUPTH-UHFFFAOYSA-N COC1=NNC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound COC1=NNC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C MKKLUEGHXQUPTH-UHFFFAOYSA-N 0.000 claims 1
- OBCDNXOFZPDSIO-GJDMYPNDSA-N C[C@]12CC(C[C@](CC1)(N2)C)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=NNC=1)O Chemical compound C[C@]12CC(C[C@](CC1)(N2)C)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=NNC=1)O OBCDNXOFZPDSIO-GJDMYPNDSA-N 0.000 claims 1
- PWCNKEWBVGFPBI-UHFFFAOYSA-N Cl.Cl.CN1C(CC(CC1(C)C)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=NNC=1)O)(C)C Chemical compound Cl.Cl.CN1C(CC(CC1(C)C)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=NNC=1)O)(C)C PWCNKEWBVGFPBI-UHFFFAOYSA-N 0.000 claims 1
- WCXRTNTVHFKOKQ-UHFFFAOYSA-N FC(OC=1C=CC(=NC=1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)F Chemical compound FC(OC=1C=CC(=NC=1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)F WCXRTNTVHFKOKQ-UHFFFAOYSA-N 0.000 claims 1
- GDAHALNLMUDALK-UHFFFAOYSA-N FC1=CC(=C(C=C1C1=CC=C(C=C1)O)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound FC1=CC(=C(C=C1C1=CC=C(C=C1)O)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C GDAHALNLMUDALK-UHFFFAOYSA-N 0.000 claims 1
- FIEBCNQTCOVUFG-UHFFFAOYSA-N FC1=NN(C=C1C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C)C Chemical compound FC1=NN(C=C1C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C)C FIEBCNQTCOVUFG-UHFFFAOYSA-N 0.000 claims 1
- UECIEINXBYIBJE-UHFFFAOYSA-N FC1=NNC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound FC1=NNC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C UECIEINXBYIBJE-UHFFFAOYSA-N 0.000 claims 1
- GWFQXHPQZZMPQA-UHFFFAOYSA-N FC=1C=NC=CC=1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound FC=1C=NC=CC=1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C GWFQXHPQZZMPQA-UHFFFAOYSA-N 0.000 claims 1
- HFBKNGRWUHFVPQ-UGKGYDQZSA-N F[C@@H]1C(NC(C[C@@H]1N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC(N(C=C1)C)=O)O)(C)C)(C)C Chemical compound F[C@@H]1C(NC(C[C@@H]1N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC(N(C=C1)C)=O)O)(C)C)(C)C HFBKNGRWUHFVPQ-UGKGYDQZSA-N 0.000 claims 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims 1
- FSQSBVAAQCSWCM-UHFFFAOYSA-N N1(C(CC(CC1(C)C)N1C2=C(N=N1)C=C(C1=CC=C(C=3C=NNC=3)C=C1O)N=N2)(C)C)C Chemical compound N1(C(CC(CC1(C)C)N1C2=C(N=N1)C=C(C1=CC=C(C=3C=NNC=3)C=C1O)N=N2)(C)C)C FSQSBVAAQCSWCM-UHFFFAOYSA-N 0.000 claims 1
- HCJOFNWJQQERIO-UHFFFAOYSA-N N1=C(C=CC=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1=C(C=CC=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C HCJOFNWJQQERIO-UHFFFAOYSA-N 0.000 claims 1
- FHQBSEMQUDGOFL-UHFFFAOYSA-N N1=CC(=CC=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1=CC(=CC=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C FHQBSEMQUDGOFL-UHFFFAOYSA-N 0.000 claims 1
- UEDXZYBNXOLLJU-UHFFFAOYSA-N N1=CC(=CC=C1)C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1=CC(=CC=C1)C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C UEDXZYBNXOLLJU-UHFFFAOYSA-N 0.000 claims 1
- XHXBXPTZXXFGET-UHFFFAOYSA-N N1=CC=C(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1=CC=C(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C XHXBXPTZXXFGET-UHFFFAOYSA-N 0.000 claims 1
- JODJSEHTXZTFLG-UHFFFAOYSA-N N1=CN=CC(=C1)C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1=CN=CC(=C1)C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C JODJSEHTXZTFLG-UHFFFAOYSA-N 0.000 claims 1
- WWUWZMDBLQKHFB-UHFFFAOYSA-N N1=NC=C(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1=NC=C(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C WWUWZMDBLQKHFB-UHFFFAOYSA-N 0.000 claims 1
- UILVXCQQVSAXPF-UHFFFAOYSA-N N1C(CC(CC1(C)C)N1C2=C(N=N1)C=C(C1=NC=C(C=C1O)C=1C=NNC=1)N=N2)(C)C Chemical compound N1C(CC(CC1(C)C)N1C2=C(N=N1)C=C(C1=NC=C(C=C1O)C=1C=NNC=1)N=N2)(C)C UILVXCQQVSAXPF-UHFFFAOYSA-N 0.000 claims 1
- BMBROBQQCKNBKO-UHFFFAOYSA-N N1C=CC=2C1=NC=CC=2C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1C=CC=2C1=NC=CC=2C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C BMBROBQQCKNBKO-UHFFFAOYSA-N 0.000 claims 1
- NQBWYLNVMBFSIN-UHFFFAOYSA-N N1CCC(CC1)C1=CNC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=NNC=1)O Chemical compound N1CCC(CC1)C1=CNC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=NNC=1)O NQBWYLNVMBFSIN-UHFFFAOYSA-N 0.000 claims 1
- RVAHNMDYQDRSDJ-UHFFFAOYSA-N N1CCC(N2C3=NC=C(N=C3C=N2)C2=CC=C(C=3C=NNC=3)C=C2O)CC1 Chemical compound N1CCC(N2C3=NC=C(N=C3C=N2)C2=CC=C(C=3C=NNC=3)C=C2O)CC1 RVAHNMDYQDRSDJ-UHFFFAOYSA-N 0.000 claims 1
- DHHGMXVHXODILS-UHFFFAOYSA-N N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)C(=CN2)C=1CC(NC(C=1)(C)C)(C)C Chemical compound N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)C(=CN2)C=1CC(NC(C=1)(C)C)(C)C DHHGMXVHXODILS-UHFFFAOYSA-N 0.000 claims 1
- XNYIAFCUBYILSN-UHFFFAOYSA-N N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)C(=CS2)C=1CCNCC=1 Chemical compound N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)C(=CS2)C=1CCNCC=1 XNYIAFCUBYILSN-UHFFFAOYSA-N 0.000 claims 1
- QUOQKLKFEJLOTO-UHFFFAOYSA-N N=1C=C(N2C=1C=NC=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N=1C=C(N2C=1C=NC=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C QUOQKLKFEJLOTO-UHFFFAOYSA-N 0.000 claims 1
- PCHPVTBEHDYBIV-UHFFFAOYSA-N N=1C=CN2C=1C=C(C=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N=1C=CN2C=1C=C(C=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C PCHPVTBEHDYBIV-UHFFFAOYSA-N 0.000 claims 1
- HEUANYLFLKGBKC-UHFFFAOYSA-N N=1C=CN2C=1C=NC(=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N=1C=CN2C=1C=NC(=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C HEUANYLFLKGBKC-UHFFFAOYSA-N 0.000 claims 1
- MHIYQAQITPPMMQ-UHFFFAOYSA-N N=1C=CN2C=1N=CC(=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N=1C=CN2C=1N=CC(=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C MHIYQAQITPPMMQ-UHFFFAOYSA-N 0.000 claims 1
- WSLLXTMQGQIZNJ-UHFFFAOYSA-N N=1C=CN2N=C(C=CC2=1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N=1C=CN2N=C(C=CC2=1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C WSLLXTMQGQIZNJ-UHFFFAOYSA-N 0.000 claims 1
- UESVQKLBZITWBV-UHFFFAOYSA-N NC1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound NC1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C UESVQKLBZITWBV-UHFFFAOYSA-N 0.000 claims 1
- LNAFRHAHLZMSDN-WGOQTCKBSA-N O\N=C\1/CCC2=CC(=C(C=C/12)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound O\N=C\1/CCC2=CC(=C(C=C/12)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C LNAFRHAHLZMSDN-WGOQTCKBSA-N 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- LRCIGPJGANAIHK-UHFFFAOYSA-N benzene-1,4-diol;dihydrochloride Chemical compound Cl.Cl.OC1=CC=C(O)C=C1 LRCIGPJGANAIHK-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 229960004337 hydroquinone Drugs 0.000 claims 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 150000002923 oximes Chemical class 0.000 claims 1
- GEOWCLRLLWTHDN-UHFFFAOYSA-N phenyl formate Chemical compound O=COC1=CC=CC=C1 GEOWCLRLLWTHDN-UHFFFAOYSA-N 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- HYHBKLWDTGTBME-UHFFFAOYSA-N pyrazin-1-ium;chloride Chemical compound Cl.C1=CN=CC=N1 HYHBKLWDTGTBME-UHFFFAOYSA-N 0.000 claims 1
- KNPBKKLNMDSNPI-UHFFFAOYSA-N pyridazin-1-ium 2,2,2-trifluoroacetate Chemical compound C1=CN=NC=C1.OC(=O)C(F)(F)F KNPBKKLNMDSNPI-UHFFFAOYSA-N 0.000 claims 1
- BEPZJGUUEAAGDN-UHFFFAOYSA-N pyridin-3-ol dihydrochloride Chemical compound Cl.Cl.Oc1cccnc1 BEPZJGUUEAAGDN-UHFFFAOYSA-N 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862690653P | 2018-06-27 | 2018-06-27 | |
US62/690,653 | 2018-06-27 | ||
PCT/US2019/038889 WO2020005873A1 (en) | 2018-06-27 | 2019-06-25 | Heterocyclic and heteroaryl compounds for treating huntington's disease |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021528467A JP2021528467A (ja) | 2021-10-21 |
JPWO2020005873A5 true JPWO2020005873A5 (lt) | 2022-06-21 |
JP7421507B2 JP7421507B2 (ja) | 2024-01-24 |
Family
ID=67180896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020572895A Active JP7421507B2 (ja) | 2018-06-27 | 2019-06-25 | ハンチントン病を処置するためのヘテロ環式およびヘテロアリール化合物 |
Country Status (22)
Country | Link |
---|---|
US (1) | US11858941B2 (lt) |
EP (2) | EP3814357B1 (lt) |
JP (1) | JP7421507B2 (lt) |
KR (1) | KR20210042265A (lt) |
CN (1) | CN112654625B (lt) |
AR (1) | AR119651A1 (lt) |
AU (2) | AU2019294478B2 (lt) |
BR (1) | BR112020026545A2 (lt) |
CA (1) | CA3103976A1 (lt) |
CL (3) | CL2020003378A1 (lt) |
CO (1) | CO2020016285A2 (lt) |
DK (1) | DK3814357T3 (lt) |
EA (1) | EA202092896A1 (lt) |
FI (1) | FI3814357T3 (lt) |
IL (1) | IL279688B1 (lt) |
LT (1) | LT3814357T (lt) |
MX (1) | MX2020014098A (lt) |
PE (1) | PE20211378A1 (lt) |
PT (1) | PT3814357T (lt) |
RS (1) | RS65727B1 (lt) |
SG (1) | SG11202012674PA (lt) |
WO (1) | WO2020005873A1 (lt) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3386511T3 (da) | 2015-12-10 | 2021-07-05 | Ptc Therapeutics Inc | Fremgangsmåder til behandling af huntingtons sygdom |
EP3634953B1 (en) | 2017-06-05 | 2024-01-03 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
WO2019005980A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | METHODS OF TREATING HUNTINGTON'S DISEASE |
EP3645121A4 (en) | 2017-06-28 | 2021-03-17 | PTC Therapeutics, Inc. | HUNTINGTON'S DISEASE TREATMENT METHODS |
EP3661509A4 (en) | 2017-08-04 | 2021-01-13 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING THE SPLICE |
BR112020012635A2 (pt) | 2017-12-22 | 2020-12-01 | Ravenna Pharmaceuticals, Inc. | derivados de aminopiridina como inibidores de fosfatidilinositol fosfato quinase |
BR112020019373A2 (pt) | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | Compostos para o tratamento da doença de hutington |
US11685746B2 (en) | 2018-06-27 | 2023-06-27 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
AU2019294478B2 (en) | 2018-06-27 | 2023-03-23 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating Huntington's disease |
JP2022521467A (ja) | 2019-02-05 | 2022-04-08 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
EP3920928A4 (en) | 2019-02-06 | 2022-09-28 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING |
EP3937942A4 (en) * | 2019-03-15 | 2022-11-16 | Skyhawk Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR CORRECTING ABERRANT SPLICING |
AU2020277027A1 (en) * | 2019-05-13 | 2021-12-09 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
EP4051280A1 (en) * | 2019-11-01 | 2022-09-07 | Novartis AG | The use of a splicing modulator for a treatment slowing progression of huntington's disease |
CN116997548A (zh) | 2020-05-13 | 2023-11-03 | Chdi基金会股份有限公司 | 用于治疗亨廷顿病的htt调节剂 |
MX2023000167A (es) | 2020-07-02 | 2023-05-03 | Remix Therapeutics Inc | Derivados de 5-[5-(piperidin-4-il)tieno[3,2-c]pirazol-2-il]indazol y compuestos relacionados como moduladores para el corte y empalme de ácidos nucleicos y para el tratamiento de enfermedades proliferativas. |
EP4175956A1 (en) | 2020-07-02 | 2023-05-10 | Remix Therapeutics Inc. | 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
WO2022060944A1 (en) * | 2020-09-16 | 2022-03-24 | Skyhawk Therapeutics, Inc. | Compositions for modulating splicing |
WO2022060951A1 (en) * | 2020-09-16 | 2022-03-24 | Skyhawk Therapeutics, Inc. | Compositions for modulating splicing |
WO2022060943A1 (en) * | 2020-09-16 | 2022-03-24 | Skyhawk Therapeutics, Inc. | Compositions for modulating splicing |
US20220162610A1 (en) * | 2020-11-12 | 2022-05-26 | Ptc Therapeutics, Inc. | Novel rna transcript |
IL302718A (en) | 2020-11-13 | 2023-07-01 | Ptc Therapeutics Inc | A tablet for use in the treatment of Huntington's disease and a method for its preparation |
EP4308572A1 (en) * | 2021-03-17 | 2024-01-24 | F. Hoffmann-La Roche AG | New thienopyrimidinone derivatives |
TW202304446A (zh) | 2021-03-29 | 2023-02-01 | 瑞士商諾華公司 | 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途 |
KR20240054264A (ko) | 2021-07-30 | 2024-04-25 | 피티씨 테라퓨틱스, 인크. | Heteroaryl compounds for treating huntington's disease |
EP4426704A1 (en) * | 2021-11-04 | 2024-09-11 | Skyhawk Therapeutics, Inc. | Condensed pyridazine amine derivatives treating sca3 |
WO2023220134A1 (en) * | 2022-05-10 | 2023-11-16 | Foghorn Therapeutics Inc. | Pyrazine derivatives and uses thereof |
WO2023244996A2 (en) * | 2022-06-15 | 2023-12-21 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating huntington's disease |
Family Cites Families (194)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE637271A (lt) | 1963-04-04 | 1900-01-01 | ||
US3558618A (en) | 1968-04-01 | 1971-01-26 | Dow Chemical Co | Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones |
GB1383409A (en) | 1972-09-09 | 1974-02-12 | Pfizer Ltd | Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them |
US4122274A (en) | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
JPS56150091A (en) | 1980-03-28 | 1981-11-20 | Janssen Pharmaceutica Nv | 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine- 4-one derivative and its manufacture |
US4342870A (en) | 1980-03-28 | 1982-08-03 | Janssen Pharmaceutica N.V. | Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives |
FR2567518B1 (fr) | 1984-07-11 | 1987-11-13 | Sanofi Sa | Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent |
US5089633A (en) | 1987-04-28 | 1992-02-18 | Georgia Tech Research Corporation | Substituted isocoumarins |
US5726182A (en) | 1990-05-02 | 1998-03-10 | Abbott Laboratories | Quinolizinone type compounds |
AU4231293A (en) | 1992-05-13 | 1993-12-13 | E.I. Du Pont De Nemours And Company | Substituted pyrido(1,2-A)pyrimidinone derivatives as fungicides |
EP1897942A1 (en) | 1993-05-11 | 2008-03-12 | The University Of North Carolina At Chapel Hill | Antisense oligonucleotides which combat aberrant splicing and methods of using the same |
IL122296A0 (en) | 1995-06-06 | 1998-04-05 | Abbott Lab | Quinolizinone type compounds |
US5916916A (en) | 1996-10-10 | 1999-06-29 | Eli Lilly And Company | 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods |
US5869500A (en) | 1996-12-13 | 1999-02-09 | Hoffmann-La Roche Inc. | Pyridone compounds useful in treating Alzheimer's disease |
CA2269561C (en) | 1998-04-22 | 2007-06-05 | Dainippon Ink And Chemicals, Inc. | Naphthalene derivative and liquid crystal composition comprising the same |
WO2000017197A1 (en) | 1998-09-21 | 2000-03-30 | Biochem Pharma Inc. | Quinolizinones as integrin inhibitors |
US6214986B1 (en) | 1998-10-07 | 2001-04-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of bcl-x expression |
US6210892B1 (en) | 1998-10-07 | 2001-04-03 | Isis Pharmaceuticals, Inc. | Alteration of cellular behavior by antisense modulation of mRNA processing |
US6172216B1 (en) | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
DE60024861T2 (de) | 1999-10-28 | 2006-07-06 | Trine Pharmaceuticals, Inc., Waltham | Pumpeninhibitoren zur freisetzung von medikamenten |
NZ520300A (en) | 2000-01-24 | 2004-05-28 | Kinacia Pty Ltd | Morpholino-substituted pyridopyrimidine, quinolone and benzopyranone derivatives that inhibit the enzyme phosphoinositide (PI) 3-kinase |
ATE544473T1 (de) | 2000-11-09 | 2012-02-15 | Cold Spring Harbor Lab | Chimäre moleküle zur modulation der genexpression |
US6774134B2 (en) | 2000-12-20 | 2004-08-10 | Bristol-Myers Squibb Company | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents |
CN100436452C (zh) | 2000-12-21 | 2008-11-26 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的吡唑化合物 |
GB0100624D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
CA2445697A1 (en) | 2001-04-26 | 2002-11-07 | Daiichi Pharmaceutical Co., Ltd. | Drug efflux pump inhibitor |
EP2198867A1 (en) | 2001-12-07 | 2010-06-23 | Vertex Pharmaceuticals, Inc. | Pyrimidine-based compounds useful as GSK-3 inhibitors |
GB0205281D0 (en) | 2002-03-06 | 2002-04-17 | Novartis Ag | Organic compounds |
ATE548354T1 (de) | 2002-07-24 | 2012-03-15 | Ptc Therapeutics Inc | Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen |
US7423133B2 (en) | 2002-08-23 | 2008-09-09 | The Board Of Trustees Of The Leland Stanford Junior University | Fluorescent glycosides and methods for their use |
DK1551835T3 (da) | 2002-09-30 | 2007-06-04 | Neurosearch As | Hidtil ukendte 1,4-diazabicycloalkanderivater, deres fremstilling og anvendelse |
US20070078144A1 (en) | 2003-01-29 | 2007-04-05 | Stockwell Brent R | Agents for treating neurodegenerative diseases |
EP1636225B1 (en) | 2003-06-20 | 2010-02-24 | Novartis Vaccines and Diagnostics, Inc. | Pyridino 1,2-a pyrimidin-4-one compounds as anticancer agents |
GB0315494D0 (en) | 2003-07-02 | 2003-08-06 | Biofocus Plc | Compounds which bind to the active site of protein kinase enzymes |
KR20060054410A (ko) | 2003-08-01 | 2006-05-22 | 제네랩스 테크놀로지스, 인코포레이티드 | 플라비비리다에에 대한 2고리 이미다졸 유도체 |
US7160888B2 (en) | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
US20050074801A1 (en) | 2003-09-09 | 2005-04-07 | Monia Brett P. | Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry |
US20050245531A1 (en) | 2003-12-22 | 2005-11-03 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
US20050137203A1 (en) | 2003-12-22 | 2005-06-23 | Jianguo Ji | 3-quinuclidinyl amino-substituted biaryl derivatives |
US7655657B2 (en) | 2003-12-22 | 2010-02-02 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
US7309699B2 (en) | 2003-12-22 | 2007-12-18 | Abbott Laboratories | 3-Quinuclidinyl amino-substituted biaryl derivatives |
BRPI0418127A (pt) | 2003-12-24 | 2007-04-27 | Biota Scient Management | uso de um composto, seus sais, e derivados farmaceuticamente aceitáveis dos mesmos, método para o tratamento de infecções envolvendo vìrus da sub-famìlia pneumovirinae, formulação farmacêutica, métodos para tratar mamìferos infectados e para prevenir a infecção de mamìferos com vìrus da sub-famìlia pneumovirinae, composto, seus sais, e derivados farmaceuticamente aceitáveis dos mesmos, composto e a forma n-óxido e sal piridìnio do mesmo, e, método de separação de enantiÈmeros de um composto |
SE0400184D0 (sv) | 2004-01-30 | 2004-01-30 | Fyrkloevern Scandinavia Ab | New therapeutical use |
TW200536830A (en) | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
AU2005232672A1 (en) | 2004-04-08 | 2005-10-27 | Neurogen Corporation | Substituted cinnolin-4-ylamines |
ES2292130T3 (es) | 2004-05-04 | 2008-03-01 | Warner-Lambert Company Llc | Pirido(2,3-d)pirimidin-7-onas pirrolil-sustituidas y derivados de las mismas como agentes terapeuticos. |
JP2008528496A (ja) | 2005-01-21 | 2008-07-31 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | エストロゲン受容体のモジュレーターとして有用な新規な複素環式ベンゾ[c]クロメン誘導体 |
US7879992B2 (en) | 2005-01-31 | 2011-02-01 | Isis Pharmaceuticals, Inc. | Modification of MyD88 splicing using modified oligonucleotides |
GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
JP2006219453A (ja) | 2005-02-14 | 2006-08-24 | Tokyo Univ Of Pharmacy & Life Science | キノリン環を母核とする金属識別型二波長性蛍光分子 |
US7563601B1 (en) | 2005-06-01 | 2009-07-21 | City Of Hope | Artificial riboswitch for controlling pre-mRNA splicing |
WO2006138418A2 (en) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
MX2007015675A (es) | 2005-07-04 | 2008-02-20 | Novo Nordisk As | Antagonistas del receptor de histamina h3. |
US7473784B2 (en) | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
WO2007047913A2 (en) | 2005-10-20 | 2007-04-26 | Isis Pharmaceuticals, Inc | Compositions and methods for modulation of lmna expression |
CA2629323A1 (en) | 2005-11-10 | 2007-05-24 | The University Of North Carolina At Chapel Hill | Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease |
WO2007065892A1 (en) | 2005-12-06 | 2007-06-14 | Neurosearch A/S | Novel diazabicyclic aryl derivatives and their medical use |
KR20080089416A (ko) | 2005-12-21 | 2008-10-06 | 페인셉터 파마 코포레이션 | 개폐 이온 통로를 조절하기 위한 조성물 및 방법 |
EP2428227B1 (en) | 2006-01-26 | 2016-06-22 | Ionis Pharmaceuticals, Inc. | Compositions and their uses directed to Huntingtin |
EP1984499B1 (en) | 2006-01-27 | 2015-05-27 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of micrornas |
AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
US8110681B2 (en) | 2006-03-17 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compounds for the treatment of spinal muscular atrophy and other uses |
NZ570524A (en) | 2006-03-28 | 2011-08-26 | High Point Pharmaceuticals Llc | Benzothiazoles having histamine H3 receptor activity |
WO2007130383A2 (en) | 2006-04-28 | 2007-11-15 | Northwestern University | Compositions and treatments using pyridazine compounds and secretases |
US20080247964A1 (en) | 2006-05-08 | 2008-10-09 | Yuelian Xu | Substituted azaspiro derivatives |
TW200812588A (en) * | 2006-05-15 | 2008-03-16 | Neurogen Corp | CRF1 receptor ligands comprising heteroaryl fused bicycles |
EP2029607A1 (en) | 2006-05-23 | 2009-03-04 | NeuroSearch A/S | Novel 8,10-diaza-bicycloý4.3.1¨decane derivatives and their medical use |
ES2344760T3 (es) | 2006-07-20 | 2010-09-06 | Amgen Inc. | Compuestos de piridona sustituidos y metodo de uso. |
WO2008013997A2 (en) | 2006-07-27 | 2008-01-31 | The Trustees Of Columbia University In The City Of New York | Fluorescent substrates for monoamine transporters as optical false neurotransmitters |
PL2066653T3 (pl) | 2006-08-03 | 2013-02-28 | Rottapharm Biotech Srl | Pochodne 6-1H-imidazo-chinazoliny i chinoliny, nowe silne środki przeciwbólowe i przeciwzapalne |
AU2007310897A1 (en) | 2006-10-25 | 2008-05-02 | Neurosearch A/S | Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators |
US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
AR064517A1 (es) | 2006-12-22 | 2009-04-08 | Avexa Ltd | Pirimidinionas biciclicas y sus usos |
WO2008083226A2 (en) | 2006-12-28 | 2008-07-10 | Navinta Llc | Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate |
FR2914188B1 (fr) | 2007-03-28 | 2012-06-22 | Trophos | Nouvelle composition a base d'oxime de cholest-4-en-3-one |
EP2014656A3 (en) | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | New heteocyclic h3 antagonists |
AU2008304231A1 (en) | 2007-09-27 | 2009-04-02 | Albany Molecular Research, Inc. | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
JP5410431B2 (ja) | 2007-09-27 | 2014-02-05 | セントロ ナシオナル デ インベスティガシオネス オンコロヒカス(セエネイオ) | イミダゾロチアジアゾール類のプロテインキナーゼ阻害剤としての使用 |
US8153813B2 (en) | 2007-12-20 | 2012-04-10 | Abbott Laboratories | Benzothiazole and benzooxazole derivatives and methods of use |
US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
WO2009126635A1 (en) | 2008-04-09 | 2009-10-15 | Abbott Laboratories | 2-amino-benzothiazole derivates useful as inhibitors of rock kinases |
US20090264433A1 (en) | 2008-04-21 | 2009-10-22 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Triazine Derivatives |
US8633019B2 (en) | 2008-05-27 | 2014-01-21 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
KR20110036583A (ko) | 2008-06-20 | 2011-04-07 | 로타팜 에스.피.에이. | 6-1h-이미다조-퀴나졸린 및 퀴놀린 유도체, 신규 mao 억제제 및 이미다졸린 수용체 리간드 |
EP2138493A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidone derivatives |
MX2011000149A (es) | 2008-07-02 | 2011-02-24 | Avexa Ltd | Compuestos que tienen propiedades antivirales. |
WO2010019236A1 (en) | 2008-08-13 | 2010-02-18 | Ptc Therapeutics, Inc | Methods for treating spinal muscular atrophy |
WO2010024903A1 (en) | 2008-08-29 | 2010-03-04 | Yangbo Feng | BENZO[d]OXAZOLES AND BENZO[d]THIAZOLES AS KINASE INHIBITORS |
WO2010045303A2 (en) | 2008-10-16 | 2010-04-22 | Schering Corporation | Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof |
GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
EP2379564A1 (en) | 2008-12-19 | 2011-10-26 | Schering Corporation | Bicyclic heterocyclic derivatives and methods of use thereof |
CA2752073A1 (en) | 2009-02-11 | 2010-08-19 | Sunovion Pharmaceuticals Inc. | Histamine h3 inverse agonists and antagonists and methods of use thereof |
FR2945289A1 (fr) | 2009-05-11 | 2010-11-12 | Sanofi Aventis | Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique |
RU2015110025A (ru) | 2009-06-19 | 2015-08-20 | Эббви Инк. | Производные диазагомоадамантана и способы их применения |
CA2773886C (en) | 2009-09-11 | 2018-01-09 | Isis Pharmaceuticals, Inc. | Modulation of huntingtin expression |
WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
US20150018301A1 (en) | 2009-11-06 | 2015-01-15 | The Johns Hopkins University | LRRK-2-Mediated Neuronal Toxicity |
EP2501231B1 (en) | 2009-11-20 | 2016-12-21 | Merck Sharp & Dohme Corp. | Quinolizidinone carboxamide m1 receptor positive allosteric modulators |
US20130012506A1 (en) | 2010-01-13 | 2013-01-10 | Zaesung No | Anti-infective pyrido (1,2-a) pyrimidines |
CA2789005A1 (en) | 2010-02-08 | 2011-08-11 | Isis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
JP2013518603A (ja) | 2010-02-08 | 2013-05-23 | アイシス ファーマシューティカルズ, インコーポレーテッド | 反復伸張に関連する疾患または病態の治療に有用な方法および組成物 |
JP6018506B2 (ja) | 2010-02-08 | 2016-11-02 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | 対立遺伝子多様体の選択的低減 |
US8877707B2 (en) | 2010-05-24 | 2014-11-04 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
CN106434648A (zh) | 2010-07-19 | 2017-02-22 | F·C·贝内特 | 肌强直性营养障碍蛋白激酶(dmpk)表达的调节 |
WO2012019106A2 (en) | 2010-08-06 | 2012-02-09 | Board Of Regents Of The University Of Nebraska | Positive and negative modulators of nmda receptors |
WO2012075393A2 (en) | 2010-12-02 | 2012-06-07 | President And Fellows Of Harvard College | Activators of proteasomal degradation and uses thereof |
CN102617548A (zh) | 2011-01-31 | 2012-08-01 | 北京赛林泰医药技术有限公司 | 作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用 |
WO2012104823A2 (en) | 2011-02-04 | 2012-08-09 | Novartis Ag | Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases |
EP3067421B1 (en) | 2011-02-08 | 2018-10-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
US8703763B2 (en) | 2011-03-02 | 2014-04-22 | Hoffmann-La Roche Inc. | Bridged piperidine derivatives |
WO2013019938A1 (en) | 2011-08-02 | 2013-02-07 | The Brigham And Women's Hospital, Inc. | Pyridazine derivatives as eaat2 activators |
WO2013022966A1 (en) | 2011-08-11 | 2013-02-14 | Isis Pharmaceuticals, Inc. | Linkage modified gapped oligomeric compounds and uses thereof |
US8871756B2 (en) | 2011-08-11 | 2014-10-28 | Hoffmann-La Roche Inc. | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease |
US20130046093A1 (en) | 2011-08-18 | 2013-02-21 | Korea Institute Of Science And Technology | Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same |
EP2751269B1 (en) | 2011-08-29 | 2016-03-23 | Ionis Pharmaceuticals, Inc. | Methods and compounds useful in conditions related to repeat expansion |
WO2013059606A1 (en) | 2011-10-21 | 2013-04-25 | Tufts Medical Center, Inc. | Compounds and methods for the treatment of muscular disease, and related screening methods |
GB201119538D0 (en) | 2011-11-10 | 2011-12-21 | Viral Ltd | Pharmaceutical compounds |
WO2013080120A1 (en) | 2011-11-28 | 2013-06-06 | Novartis Ag | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
JP6193881B2 (ja) | 2011-12-30 | 2017-09-06 | ピーティーシー セラピューティクス, インコーポレイテッド | 脊髄性筋萎縮症を治療するための化合物 |
KR102064624B1 (ko) | 2012-01-26 | 2020-01-09 | 피티씨 테라퓨틱스, 인크. | 척수성 근위축증을 치료하기 위한 화합물 |
ES2697174T3 (es) | 2012-02-10 | 2019-01-22 | Ptc Therapeutics Inc | Compuestos para tratar atrofia muscular espinal |
WO2013130689A1 (en) | 2012-03-01 | 2013-09-06 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
BR112014023483B1 (pt) | 2012-03-23 | 2022-05-10 | Ptc Therapeutics, Inc | Composto e seu uso, composição farmacêutica e seu uso |
RS61664B1 (sr) | 2012-04-24 | 2021-04-29 | Vertex Pharma | Inhibitori dna-pk |
US9212209B2 (en) | 2012-07-13 | 2015-12-15 | Indiana University Research And Technology Corporation | Screening methods for spinal muscular atrophy |
US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
EP2906255B1 (en) | 2012-10-12 | 2023-02-22 | Ionis Pharmaceuticals, Inc. | Antisense compounds and uses thereof |
WO2014059356A2 (en) | 2012-10-12 | 2014-04-17 | Isis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
JP6291502B2 (ja) * | 2012-10-25 | 2018-03-14 | アッシャー・サード・イニシアティブ・インコーポレイテッド | ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法 |
US9227976B2 (en) * | 2012-10-25 | 2016-01-05 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
JP6255711B2 (ja) | 2012-11-01 | 2018-01-10 | 株式会社リコー | エレクトロクロミック化合物、エレクトロクロミック組成物及び表示素子 |
US9040712B2 (en) | 2013-01-23 | 2015-05-26 | Novartis Ag | Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions |
WO2014121287A2 (en) | 2013-02-04 | 2014-08-07 | Isis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
AU2014224975B2 (en) | 2013-03-05 | 2017-09-14 | Merck Patent Gmbh | Triazolo(4,5-d)pyrimidine derivatives for the treatment of diseases such as cancer |
RU2015148926A (ru) | 2013-05-14 | 2017-06-15 | Ф. Хоффманн-Ля Рош Аг | Аза-оксо-индолы для лечения и профилактики респираторно-синцитиальной вирусной инфекции |
BR112015030288B1 (pt) | 2013-06-25 | 2022-10-18 | Ptc Therapeutics, Inc. | Compostos e seu uso no tratamento de atrofia muscular espinhal |
KR20210130843A (ko) | 2013-07-31 | 2021-11-01 | 노파르티스 아게 | 1,4-이치환된 피리다진 유사체 및 smn-결핍-관련 상태를 치료하기 위한 그의 용도 |
EP3035935B1 (en) | 2013-08-19 | 2020-03-11 | F. Hoffmann-La Roche AG | Compounds for use in the prophylaxis and treatment of cancer |
WO2015095446A1 (en) | 2013-12-19 | 2015-06-25 | Ptc Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
US10195202B2 (en) | 2013-12-19 | 2019-02-05 | Ptc Therapeutics, Inc. | Methods for modulating the amount of RNA transcripts |
WO2015095449A1 (en) | 2013-12-19 | 2015-06-25 | Ptc Therapeutics, Inc. | Methods for modulating the amount rna transcripts |
EP3087067B1 (en) * | 2013-12-26 | 2018-10-24 | Takeda Pharmaceutical Company Limited | 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors |
PT3094728T (pt) | 2014-01-16 | 2022-05-19 | Wave Life Sciences Ltd | Desenho quiral |
JP6473457B2 (ja) | 2014-01-17 | 2019-02-20 | ノバルティス アーゲー | Shp2の活性を阻害するための1−(トリアジン−3−イル/ピリダジン−3−イル)−ピペリジン/ピペラジン誘導体およびその組成物 |
AR099134A1 (es) | 2014-01-24 | 2016-06-29 | Hoffmann La Roche | Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina |
RU2683309C2 (ru) | 2014-03-14 | 2019-03-28 | Раквалиа Фарма Инк. | Азаспиропроизводные в качестве антагонистов trpm8 |
WO2015143185A1 (en) | 2014-03-19 | 2015-09-24 | Amydis Diagnostics | Amyloid targeting agents and methods of using the same |
PT3143025T (pt) | 2014-05-15 | 2019-12-03 | Hoffmann La Roche | Compostos para tratamento da atrofia muscular espinhal |
GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
CN106573811A (zh) | 2014-06-17 | 2017-04-19 | 诺维信公司 | 从废水中去除生物磷 |
RU2725979C2 (ru) | 2014-06-25 | 2020-07-08 | Ф. Хоффманн-Ля Рош Аг | ИМИДАЗО[1,2-а]ПИРАЗИН-1-ИЛ-БЕНЗАМИДЫ ДЛЯ ЛЕЧЕНИЯ СПИНАЛЬНОЙ МЫШЕЧНОЙ АТРОФИИ |
JP2018500302A (ja) | 2014-12-02 | 2018-01-11 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 有害生物防除剤としての二環式化合物 |
CN108064292B (zh) | 2014-12-24 | 2021-05-04 | 尤尼克尔生物制药股份有限公司 | RNAi诱导的亨廷顿蛋白基因抑制 |
TW202204345A (zh) | 2015-01-16 | 2022-02-01 | 美商通用醫院公司 | 改善mRNA剪接之化合物 |
EP3256126B1 (en) | 2015-02-09 | 2024-03-27 | F. Hoffmann-La Roche AG | Compounds for the treatment of cancer |
GB201502567D0 (en) | 2015-02-16 | 2015-04-01 | Sentinel Oncology Ltd | Pharmaceutical compounds |
CN107635984B (zh) | 2015-03-11 | 2021-04-13 | Fmc公司 | 杂环取代的二环唑杀有害生物剂 |
GB201506933D0 (en) | 2015-04-23 | 2015-06-10 | Sentinel Oncology Ltd | Pharmaceutical compounds |
WO2016184832A1 (en) | 2015-05-20 | 2016-11-24 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
WO2016196386A1 (en) | 2015-05-30 | 2016-12-08 | Ptc Therapeutics, Inc. | Methods for modulating rna splicing |
MA43072A (fr) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
WO2017023987A1 (en) * | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
TW201718546A (zh) | 2015-10-02 | 2017-06-01 | 英塞特公司 | 適用作pim激酶抑制劑之雜環化合物 |
JP2018533594A (ja) | 2015-11-12 | 2018-11-15 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 筋萎縮性側索硬化症を処置するための化合物 |
AU2016353961B2 (en) | 2015-11-12 | 2019-08-29 | F. Hoffmann-La Roche Ag | Compositions for treating spinal muscular atrophy |
US10383867B2 (en) | 2015-11-28 | 2019-08-20 | Russell Dahl | Quinoline derivatives and their use for treating endoplasmic reticulum stress-related diseases and disorders |
JP6872550B2 (ja) | 2015-12-10 | 2021-05-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 架橋されたピペリジン誘導体 |
DK3386511T3 (da) * | 2015-12-10 | 2021-07-05 | Ptc Therapeutics Inc | Fremgangsmåder til behandling af huntingtons sygdom |
US10526345B2 (en) | 2016-04-08 | 2020-01-07 | Mankind Pharma Ltd. | Compounds as GPR119 agonists |
AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
MA45270A (fr) | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
AU2017274199B2 (en) * | 2016-05-31 | 2021-09-23 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
US20190264267A1 (en) | 2016-07-25 | 2019-08-29 | Wave Life Sciences Ltd. | Phasing |
WO2018081091A1 (en) * | 2016-10-24 | 2018-05-03 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
US11857599B2 (en) | 2017-04-03 | 2024-01-02 | Acceleron Pharma Inc. | Compositions and methods for treating spinal muscular atrophy |
EP3630770B1 (en) * | 2017-05-26 | 2024-08-28 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
EP3634953B1 (en) | 2017-06-05 | 2024-01-03 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
WO2019005980A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | METHODS OF TREATING HUNTINGTON'S DISEASE |
EP3645121A4 (en) | 2017-06-28 | 2021-03-17 | PTC Therapeutics, Inc. | HUNTINGTON'S DISEASE TREATMENT METHODS |
EP3661509A4 (en) | 2017-08-04 | 2021-01-13 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING THE SPLICE |
WO2019165073A1 (en) | 2018-02-21 | 2019-08-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
WO2019183364A1 (en) * | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof |
TW202003471A (zh) | 2018-03-21 | 2020-01-16 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
BR112020019373A2 (pt) | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | Compostos para o tratamento da doença de hutington |
AU2019294478B2 (en) | 2018-06-27 | 2023-03-23 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating Huntington's disease |
KR20210038845A (ko) | 2018-06-27 | 2021-04-08 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료를 위한 헤테로아릴 화합물 |
US11685746B2 (en) | 2018-06-27 | 2023-06-27 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
EP3937942A4 (en) | 2019-03-15 | 2022-11-16 | Skyhawk Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR CORRECTING ABERRANT SPLICING |
AU2020277027A1 (en) | 2019-05-13 | 2021-12-09 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
WO2021007378A1 (en) | 2019-07-11 | 2021-01-14 | Ptc Therapeutics, Inc. | Compounds for use in treating huntington's disease |
EP4051280A1 (en) | 2019-11-01 | 2022-09-07 | Novartis AG | The use of a splicing modulator for a treatment slowing progression of huntington's disease |
CA3173903A1 (en) | 2020-04-09 | 2021-10-14 | Nadiya Sydorenko | Compounds for treating huntington's disease |
US20220162610A1 (en) | 2020-11-12 | 2022-05-26 | Ptc Therapeutics, Inc. | Novel rna transcript |
KR20240054264A (ko) | 2021-07-30 | 2024-04-25 | 피티씨 테라퓨틱스, 인크. | Heteroaryl compounds for treating huntington's disease |
-
2019
- 2019-06-25 AU AU2019294478A patent/AU2019294478B2/en active Active
- 2019-06-25 EP EP19736566.1A patent/EP3814357B1/en active Active
- 2019-06-25 RS RS20240779A patent/RS65727B1/sr unknown
- 2019-06-25 CA CA3103976A patent/CA3103976A1/en active Pending
- 2019-06-25 KR KR1020207036440A patent/KR20210042265A/ko not_active Application Discontinuation
- 2019-06-25 MX MX2020014098A patent/MX2020014098A/es unknown
- 2019-06-25 EP EP24168248.3A patent/EP4434990A1/en active Pending
- 2019-06-25 DK DK19736566.1T patent/DK3814357T3/da active
- 2019-06-25 IL IL279688A patent/IL279688B1/en unknown
- 2019-06-25 SG SG11202012674PA patent/SG11202012674PA/en unknown
- 2019-06-25 PE PE2020002185A patent/PE20211378A1/es unknown
- 2019-06-25 CN CN201980051041.4A patent/CN112654625B/zh active Active
- 2019-06-25 JP JP2020572895A patent/JP7421507B2/ja active Active
- 2019-06-25 PT PT197365661T patent/PT3814357T/pt unknown
- 2019-06-25 US US17/254,660 patent/US11858941B2/en active Active
- 2019-06-25 EA EA202092896A patent/EA202092896A1/ru unknown
- 2019-06-25 FI FIEP19736566.1T patent/FI3814357T3/fi active
- 2019-06-25 WO PCT/US2019/038889 patent/WO2020005873A1/en active Application Filing
- 2019-06-25 BR BR112020026545-4A patent/BR112020026545A2/pt unknown
- 2019-06-25 LT LTEPPCT/US2019/038889T patent/LT3814357T/lt unknown
- 2019-06-28 AR ARP190101808A patent/AR119651A1/es unknown
-
2020
- 2020-12-23 CL CL2020003378A patent/CL2020003378A1/es unknown
- 2020-12-24 CO CONC2020/0016285A patent/CO2020016285A2/es unknown
-
2021
- 2021-11-16 CL CL2021003022A patent/CL2021003022A1/es unknown
-
2022
- 2022-12-02 CL CL2022003434A patent/CL2022003434A1/es unknown
-
2023
- 2023-05-23 AU AU2023203241A patent/AU2023203241A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPWO2020005873A5 (lt) | ||
US12084447B2 (en) | SHP2 phosphatase inhibitors and methods of use thereof | |
JP7399869B2 (ja) | ハンチントン病を処置するための化合物 | |
JPWO2020005877A5 (lt) | ||
JP2021503004A5 (lt) | ||
AU2021202398A1 (en) | Bicyclic lactams and methods of use thereof | |
DK2773638T3 (en) | HETEROARYLPYRIDON AND AZA PYRIDON COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | |
JP2017518326A5 (lt) | ||
JP2020522570A5 (lt) | ||
JP2014528482A5 (lt) | ||
US20170145034A1 (en) | Alkynyl alcohols and methods of use | |
HRP20151232T1 (hr) | Derivati 2,3-dihidro-1h-inden-1-il-2,7-diazaspiro[3.6]nonana i njihova upotreba kao antagonista ili inverznih agonista grelinskog receptora | |
JP2020526549A5 (lt) | ||
JP2018527353A5 (lt) | ||
JP2016525092A5 (lt) | ||
JP2013523884A5 (lt) | ||
JP2014506929A5 (lt) | ||
JP2015537010A5 (lt) | ||
RU2013136778A (ru) | Ингибиторы гистондезацетилазы, композиции и способы их применения | |
JPWO2020231977A5 (lt) | ||
IL297044A (en) | Compounds for the treatment of Huntington's disease | |
JP2013518823A5 (lt) | ||
RU2020127848A (ru) | Производные 4-гидроксипиперидина и их применение в качестве ингибиторов убиквитин-специфической протеазы 19 (usp19) | |
JPWO2020065613A5 (lt) | ||
JPWO2019156987A5 (lt) |